Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review

Yu Shan Huang, Jen Jia Yang, Nan Yao Lee, Guan Jhou Chen, Wen Chien Ko, Hsin Yun Sun, Chien Ching Hung

研究成果: Review article同行評審

15 引文 斯高帕斯(Scopus)

摘要

Introduction: Pneumocystis pneumonia is a potentially life-threatening pulmonary infection that occurs in immunocompromised individuals and HIV-infected patients with a low CD4 cell count. Trimethoprim-sulfamethoxazole has been used as the first-line agent for treatment, but mutations within dihydropteroate synthase gene render potential resistance to sulfamide. Despite advances of combination antiretroviral therapy (cART), Pneumocystis pneumonia continues to occur in HIV-infected patients with late presentation for cART or virological and immunological failure after receiving cART. Areas covered: This review summarizes the diagnosis and first-line and alternative treatment and prophylaxis for Pneumocystis pneumonia in HIV-infected patients. Articles for this review were identified through searching PubMed. Search terms included: ‘Pneumocystis pneumonia’, ‘Pneumocystis jirovecii pneumonia’, ‘Pneumocystis carinii pneumonia’, ‘trimethoprim-sulfamethoxazole’, ‘primaquine’, ‘trimetrexate’, ‘dapsone’, ‘pentamidine’, ‘atovaquone’, ‘echinocandins’, ‘human immunodeficiency virus infection’, ‘acquired immunodeficiency syndrome’, ‘resistance to sulfamide’ and combinations of these terms. We limited the search to English language papers that were published between 1981 and March 2017. We screened all identified articles and cross-referenced studies from retrieved articles. Expert commentary: Trimethoprim-sulfamethoxazole will continue to be the first-line agent for Pneumocystis pneumonia given its cost, availability of both oral and parenteral formulations, and effectiveness or efficacy in both treatment and prophylaxis. Whether resistance due to mutations within dihydropteroate synthase gene compromises treatment effectiveness remains controversial. Continued search for effective alternatives with better safety profiles for Pneumocystis pneumonia is warranted.

原文English
頁(從 - 到)873-892
頁數20
期刊Expert Review of Anti-Infective Therapy
15
發行號9
DOIs
出版狀態Published - 2017 九月 2

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases

指紋 深入研究「Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review」主題。共同形成了獨特的指紋。

引用此